"TCI offers full-service heart and vascular care throughout mid-Michigan, offering Patients the newest and most exciting treatment options available."

During the past decade, Thoracic Cardiovascular Healthcare Foundation conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 8 clinical trials were completed, i.e. on average, 400% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 4 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Thoracic Cardiovascular Healthcare Foundation" #1 sponsor was "Abbott Medical Devices" with 8 trials, followed by "Anesiva, Inc." with 2 trials sponsored, "Angiotech Pharmaceuticals" with 2 trials sponsored, "Bristol-Myers Squibb" with 2 trials sponsored and "Forest Laboratories" with 2 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Thoracic Cardiovascular Healthcare Foundation" #1 collaborator was "AtriCure, Inc." with 1 trials as a collaborator, "Duke Clinical Research Institute" with 1 trials as a collaborator, "Medtronic" with 1 trials as a collaborator, "Pfizer" with 1 trials as a collaborator and "University of Zurich" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Thoracic Cardiovascular Healthcare Foundation" are "Heart Failure" (7 trials), "Atrial Fibrillation" (5 trials), "Coronary Artery Disease" (4 trials), "Hyperplasia" (2 trials) and "Acute Coronary Syndrome" (1 trials). Many other conditions were trialed in "Thoracic Cardiovascular Healthcare Foundation" in a lesser frequency.

Most popular intervention types in "Thoracic Cardiovascular Healthcare Foundation" are "Device" (11 trials), "Drug" (8 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Azimilide Dihydrochloride" (2 trials), "Accent MRI system (lead safety)" (1 trials), "Accent MRI system (with MRI scan)" (1 trials) and "Apixaban" (1 trials). Other intervention names were less common.

The vast majority of trials in "Thoracic Cardiovascular Healthcare Foundation" are 22 trials for "All" genders.

Currently, there are NaN active trials in "Thoracic Cardiovascular Healthcare Foundation". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in Thoracic Cardiovascular Healthcare Foundation, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Thoracic Cardiovascular Healthcare Foundation, 1 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 8 trials that are defined as “Not Applicable".